Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyperprolactinemia resistant to dopamine agonists

López, José Manuel; Oestreicher, Eveline

doi:10.1016/j.fertnstert.2005.05.006

Cited by 7 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical studies have confirmed that ER expression is positively correlated with tumour PRL level and is significantly increased in invasive PRLomas . Conversely, ER antagonist fulvestrant showed reduced size and PRL secretion of PRLomas, and tamoxifen was successfully used to treat a dopamine agonist‐resistant PRLoma . These data, together, suggest that ER may be responsible for the anti‐PRLoma activity of MET and for its reported sexual dimorphism of the anti‐PRLoma activity …”

Section: Discussionmentioning

confidence: 90%

“…We found here for the first time that MET suppresses ERα and ERβ expression in PRLoma cells and their xenografts. Studies have suggested critical roles for oestrogen and its receptors in the development of PRLoma . Oestrogens retard the effects of dopamine agonists, with direct action on PRL gene transcription, stimulation of mitotic activity, and modulation of the inhibiting effect of dopamine on PRL gene transcription .…”

Section: Discussionmentioning

confidence: 99%

“…35 Conversely, ER antagonist fulvestrant showed reduced size and PRL secretion of PRLomas, 16,36 and tamoxifen was successfully used to treat a dopamine agonist-resistant PRLoma. 37 These data, together, suggest that ER may be responsible for the anti- F I G U R E 3 Metformin activates AMPK, suppressed proliferation, but has no significant effect on apoptosis of both the bromocriptinesensitive MMQ cells and the bromocriptine-resistant GH3 cells. A, MMQ and GH3 cells were treated with metformin of indicated concentrations for 24 hours before subjected to western blotting analysis of AMPK and pAMPK levels.…”

Section: Met Reduces Er Expression In Prloma Cells and Xenograftsmentioning

confidence: 93%

“…Studies have suggested critical roles for oestrogen and its receptors in the development of PRLoma. 16,[30][31][32][33][34][35][36][37] Oestrogens retard the effects of dopamine agonists, with direct action on PRL gene transcription, stimulation of mitotic activity, and modulation of the inhibiting effect of dopamine on PRL gene transcription. 30 Prolonged oestrogen administration in animals, and also in men, induced the appearance of pituitary tumours, especially PRLomas.…”

Section: Met Reduces Er Expression In Prloma Cells and Xenograftsmentioning

confidence: 99%

See 3 more Smart Citations

Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts

Gao

Liu

Han

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

Metformin (MET) is a diabetes drug that activates AMP‐activated protein kinase (AMPK), and is suggested to have anticancer efficacy. Here, we investigated the role of AMPK signalling in prolactinoma (PRLoma), with particular respect to MET and bromocriptine (BC) as a PRLoma treatment. We analysed AMPK phosphorylation, dopamine D2 receptor (D2R), and oestrogen receptor (ER) expression in both BC‐sensitive and ‐resistant PRLoma samples; effects of the AMPK agonist MET (alone or with BC) on in vitro proliferation and apoptosis, xenograft growth and prolactin (PRL) secretion of BC‐sensitive and ‐resistant cells, and ER expression in xenografts. Some BC‐resistant PRLomas showed high D2R expression but extremely low AMPK activation. MET significantly inhibited proliferation of cultured PRLoma cells; MET + BC notably restrained their PRL secretion. MET + BC further decreased tumour growth and serum PRL levels in xenografts than BC treatment alone. ER was down‐regulated after AMPK activation in both cultured cells and xenografts. Together, we propose that the AMPK signalling pathway down‐regulates ERα and ERβ, and suppresses PRLoma growth as well as PRL secretion. Combined MET + BC is a potential treatment for PRLomas.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Met Reduces Er Expression In Prloma Cells and Xenograftsmentioning

confidence: 93%

Section: Met Reduces Er Expression In Prloma Cells and Xenograftsmentioning

confidence: 99%

See 2 more Smart Citations

Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts

Gao

Liu

Han

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Given this hypothesis, prolactinomas that are resistant to dopamine agonist treatment may be managed by using estrogen receptor antagonists; indeed, a previous study showed that an estrogen receptor antagonist, tamoxifen, successfully treated patients with dopamine agonist-resistant prolactinomas. 32…”

Section: Discussionmentioning

confidence: 99%

Increased expression of aromatase cytochrome P450 enzyme is associated with prolactinoma invasiveness in post-menopausal women

Shen

et al. 2019

J Int Med Res

View full text Add to dashboard Cite

Objectives To investigate the expression levels of aromatase cytochrome P450 enzyme (P450AROM) and related molecules—estrogen receptor-beta (ER-β), Ki-67, and p53—in prolactinoma tumor tissue from pre- and post-menopausal women, and to determine the associations of tumor invasiveness with expression levels of these genes. Methods This study recruited 90 patients with prolactinoma who underwent adenoidectomy between 2012 and 2017. Information was collected regarding clinical characteristics, hormones, laboratory tests, and magnetic resonance imaging-assessed tumor invasiveness. Expression levels of P450AROM, ER-β, Ki-67, and p53 were examined by immunohistochemistry in prolactinoma tissues. Results Increased P450AROM expression was found in invasive prolactinoma tissues in post-menopausal women, compared with its expression in non-invasive prolactinoma tissues. ER-β level was significantly higher in patients resistant to treatment with bromocriptine, a dopamine agonist. However, there were no differences in rate of resistance to treatment (8.2% vs. 3.4%) or expression levels of P450AROM, Ki-67, p53, and ER-β between pre- and post-menopausal patients. Conclusions Our results demonstrated that increased P450AROM expression in prolactinoma of post-menopausal women was positively associated with invasiveness. Moreover, ER-β level was higher in both pre- and post-menopausal patients who were resistant to dopamine agonist treatment.

show abstract

Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas

Bai

Gui

Zhang

2013

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyperprolactinemia resistant to dopamine agonists

Cited by 7 publications

References 19 publications

Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts

Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts

Increased expression of aromatase cytochrome P450 enzyme is associated with prolactinoma invasiveness in post-menopausal women

Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas

Contact Info

Product

Resources

About